Hydroxybenzaldoximes Are D‐GAP‐Competitive Inhibitors of E. coli 1‐Deoxy‐D‐Xylulose‐5‐Phosphate Synthase |
| |
| Authors: | David Bartee Dr Francine Morris Amer Al‐khouja Prof Caren L Freel Meyers |
| |
| Affiliation: | 1. Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 (USA);2. Present address: Albert Einstein College of Medicine, Department of Biochemistry, 1301 Morris Park Avenue, Bronx, NY 10461 (USA) |
| |
| Abstract: | 1‐Deoxy‐D ‐xylulose 5‐phosphate (DXP) synthase is the first enzyme in the methylerythritol phosphate pathway to essential isoprenoids in pathogenic bacteria and apicomplexan parasites. In bacterial pathogens, DXP lies at a metabolic branch point, serving also as a precursor in the biosynthesis of vitamins B1 and B6, which are critical for central metabolism. In an effort to identify new bisubstrate analogue inhibitors that exploit the large active site and distinct mechanism of DXP synthase, a library of aryl mixed oximes was prepared and evaluated. Trihydroxybenzaldoximes emerged as reversible, low‐micromolar inhibitors, competitive against D ‐glyceraldehyde 3‐phosphate (D ‐GAP) and either uncompetitive or noncompetitive against pyruvate. Hydroxybenzaldoximes are the first class of D ‐GAP‐competitive DXP synthase inhibitors, offering new tools for mechanistic studies of DXP synthase and a new direction for the development of antimicrobial agents targeting isoprenoid biosynthesis. |
| |
| Keywords: | biosynthesis DXP synthase inhibitors isoprenoids MEP pathway thiamin diphosphate |
|
|
